Proportion of participants with treatment‐emergent adverse events (TEAEs) ‐ Leading to discontinuation during the treatment period № of participants: 36 (1 RCT) · people with newly diagnosed epilepsy
It is very uncertain whether clonazepam changes proportion of participants with treatment‐emergent adverse events… compared with carbamazepine (very low certainty).
1 finding from 1 review
RR 2.61 [0.8, 8.52]
Studies not reported
Very low
Proportion of participants seizure‐free at 12 months after randomization · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion free from seizures (Engel Class 1) at 2 years · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% or greater reduction in seizure frequency · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events during treatment period · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment withdrawal · people with epilepsy
1 finding from 1 review
Adverse effects (cardiac) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (cardiac) compared with levetiracetam (low certainty).
1 finding from 1 review
Gastrointestinal adverse events · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (gastrointestinal) compared with levetiracetam (low certainty).
1 finding from 1 review
Adverse effects (bones and muscles) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (bones and muscles) compared with levetiracetam (low certainty).
1 finding from 1 review
Adverse effects (others) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (others) compared with levetiracetam (low certainty).
1 finding from 1 review
Treatment withdrawal · participants with epilepsy (GTCS)
1 finding from 1 review
Seizure freedom · participants with epilepsy (GTCS)
1 finding from 1 review
All adverse effects · participants with epilepsy (GTCS)
Sulthiame showed no clear difference in all adverse effects compared with phenytoin (low certainty).
1 finding from 1 review
Paraesthesia · participants with epilepsy (GTCS)
Sulthiame showed no clear difference in paraesthesia compared with phenytoin (low certainty).
1 finding from 1 review
Dizziness · participants with epilepsy (GTCS)
Sulthiame showed no clear difference in dizziness compared with phenytoin (low certainty).
1 finding from 1 review
Headache · participants with epilepsy (GTCS)
Sulthiame showed no clear difference in headache compared with phenytoin (low certainty).
1 finding from 1 review
Seizure freedom · people with epilepsy
1 finding from 1 review
Anorexia · participants with epilepsy (GTCS)
Sulthiame showed no clear difference in anorexia compared with phenytoin (low certainty).
1 finding from 1 review
Rash · participants with epilepsy (GTCS)
Sulthiame showed no clear difference in rash compared with phenytoin (low certainty).
1 finding from 1 review
Gingival hyperplasia · participants with epilepsy (GTCS)
Sulthiame may leads to lower gingival hyperplasia compared with phenytoin (low certainty).
1 finding from 1 review